University of Vermont

The University of Vermont Cancer Center


Melanoma Clinical Trials

The University of Vermont Cancer Center has many trials specifically focused on skin cancer research.

Status: Active - Recruiting

Study Title: A Phase III Randomized Study of Adjuvant Ipilimumab Anti-CTLA4 Therapy Versus High-Dose Interferon a-2b for Resected High-Risk Melanoma

Purpose: The purpose of this study is to compare the effects, good and/or bad, of ipilimumab with interferon alfa-2b on you and your melanoma to find out which is better.  In this study, you will get either ipilimumab or the interferon alfa-2b. You will not get both. We plan to determine whether ipilimumab stops or delays your cancer from returning in comparison to interferon alfa-2b. Identifier: N/A
Primary/Site/Co Investigator: Steven Emmons, MD
Contact: Elizabeth Eldridge (802) 656-2178
Information: N/A
Institution Number: M12-125 ECOG-ACRIN 1609
Protocol Research Type: Cooperative Group - ECOG-ACRIN
Status: Active - Recruiting

Study Title: A Phase I/II, Open Label Study of Ad-RTS-hIL-12, an Adenovirus Vector Engineered to Express hIL-12, in Combination with an Oral Activator Ligand, in Subjects with Unresectable Stage III or IV Melanoma. 

Purpose: The purpose of this study is to evaluate the safety and tolerability of intratumoral injections of INXN-2001 at a constant dose in combination with and oral drug INXN-1001 in patients who have unresectable stage III or IV melanoma.  Additional this study will be evaluating anti-tumor activity (as evidenced by reduction in the size of melanoma tumors). Identifier: NCT01397708
Primary/Site/Co Investigator: Claire Verschraegen, MD
Contact: Kate Murray (802) 656-9401
Institution Number: M13-027
Protocol Research Type: Industry Sponsored

Last modified December 05 2014 11:48 AM